Health Catalyst, Inc.
NASDAQ:HCATMedical - Healthcare Information Services
-$0.04 today
- Market cap
- $98.24M
- Beta
- 1.66
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$3.65
Volume 0.27M
Average 1.24M
HCAT Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Health Catalyst, Inc.NASDAQ: HCAT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $12.12M fell 1.7% year over year, behind the +16.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.0% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Depreciation & amortization amounted to 16.2% of revenue in FY2025, up 2.7 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -1.7% toward the trailing-twelve-month pace of +16.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 50.5M USD
- Year-over-year change
- +21.9%
- 4-year CAGR
- +5.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.5M | +21.9% |
| FY2024 | 2024-12-31 | 41.43M | -1.9% |
| FY2023 | 2023-12-31 | 42.22M | -18.1% |
| FY2022 | 2022-12-31 | 51.53M | +25.3% |
| FY2021 | 2021-12-31 | 41.11M | — |
Depreciation & Amortization vs competitors
How HCAT compares with its peers on the latest reported figures
- HCAT's LTM Mar 2026 depreciation & amortization of $50.3M is the highest of the 11 companies compared; the peer median is $2.93M.
- Its year-over-year change of +16.4% is the 5th highest of 11, against a peer median of +2.5%.
- Depreciation & amortization amounts to 16.6% of revenue for HCAT, versus a peer median of 8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.3M | +16.4% | -0.7% | 16.6% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $4.93M | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.74M | -56.6% | -11.6% | 2.3% | |
| LTM Mar 2026 | $1.67M | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $1.59M | +32.3% | +10.5% | 3.6% | |
| LTM Mar 2026 | $672K | +1192.3% | +38.7% | 7.0% | |
| LTM Mar 2026 | $334K | +5.4% | +13.8% | 1.0% | |
| Peer median (excluding HCAT) | $2.93M | +2.5% | +9.7% | 8.5% | |
Competitors are the stored peer set for HCAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 241.93M | 276.24M | 295.94M | 306.58M | 311.14M |
| Cost of Revenue | 124.35M | 143.05M | 164.11M | 165.81M | 207M |
| Gross Profit | 117.57M | 133.19M | 131.83M | 140.78M | 104.13M |
| Gross Margin | 48.6% | 48.2% | 44.5% | 45.9% | 33.5% |
| Research & Development | 62.73M | 75.68M | 72.63M | 57.95M | 49.77M |
| Selling, General & Admin | 160.96M | 149.22M | 143.88M | 111.2M | 102.04M |
| Operating Expenses | 261.22M | 273.19M | 258.73M | 210.59M | 140.24M |
| Depreciation & Amortization | 41.11M | 51.53M | 42.22M | 41.43M | 50.5M |
| EBITDA | (101.68M) | (82.92M) | (68.28M) | (10.65M) | (110.35M) |
| EBITDA Margin | -42.0% | -30.0% | -23.1% | -3.5% | -35.5% |
| Operating Income | (143.65M) | (140.01M) | (126.9M) | (69.81M) | (36.1M) |
| Operating Margin | -59.4% | -50.7% | -42.9% | -22.8% | -11.6% |
| Interest Income | 831K | 5.69M | 16.39M | 17.98M | 7.54M |
| Interest Expense | 17.31M | 7.24M | 7.29M | 17.09M | 16.4M |
| Other Income / Expenses | (16.46M) | (1.68M) | 9.11M | 637K | (141.15M) |
| Income Before Tax | (160.11M) | (141.68M) | (117.79M) | (69.17M) | (177.26M) |
| Pre-Tax Margin | -66.2% | -51.3% | -39.8% | -22.6% | -57.0% |
| Income Tax Expense | (6.9M) | (4.28M) | 356K | 333K | 716K |
| Net Income | (153.21M) | (137.4M) | (118.15M) | (69.5M) | (177.97M) |
| Net Margin | -63.3% | -49.7% | -39.9% | -22.7% | -57.2% |
| EPS (Basic) | (3.23) | (2.56) | (2.09) | (1.15) | (2.55) |
| EPS (Diluted) | (3.23) | (2.54) | (2.09) | (1.15) | (2.55) |
| Weighted Avg Shares | 47.49M | 53.72M | 56.42M | 60.19M | 69.9M |
| Weighted Avg Shares (Diluted) | 47.49M | 54.08M | 56.42M | 60.19M | 69.9M |
Health Catalyst, Inc.
NASDAQ:HCAT
Intrinsic Alpha fair value
Locked
Current Price
$1.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.